Glycopyrronium Once-daily Significantly Improves Lung Function and Health Status when Combined with Salmeterol/fluticasone in Patients with COPD: the GLISTEN Study, a Randomised Controlled Trial

Overview

Journal Thorax

Date 2015 Apr 5

PMID 25841237

Citations 34

Authors

Peter A Frith

Philip J Thompson

Rajeev Ratnavadivel

Catherina L Chang

Peter Bremner

Peter Day

Christina Frenzel

Nicol Kurstjens

Affiliations

Soon will be listed here.

Abstract

Background: The optimal use of various therapeutic combinations for moderate/severe chronic obstructive pulmonary disease (COPD) is unclear. The GLISTEN trial compared the efficacy of two long-acting anti-muscarinic antagonists (LAMA), when combined with an inhaled corticosteroid (ICS) and a long-acting β2 agonist (LABA).

Methods: This randomised, blinded, placebo-controlled trial in moderate/severe COPD patients compared once-daily glycopyrronium (GLY) 50 µg, once-daily tiotropium (TIO) 18 µg or placebo (PLA), when combined with salmeterol/fluticasone propionate (SAL/FP) 50/500 µg twice daily. The primary objective was to determine the non-inferiority of GLY+SAL/FP versus TIO+SAL/FP on trough FEV1 after 12 weeks. An important secondary objective was whether addition of GLY to SAL/FP was better than SAL/FP alone.

Results: 773 patients (mean FEV1 57.2% predicted) were randomised; 84.9% completed the trial. At week 12, GLY+SAL/FP demonstrated non-inferiority to TIO+SAL/FP for trough FEV1: least square mean treatment difference (LSMdiff) -7 mL (SE 17.4) with a lower limit for non-inferiority of -60 mL. There was significant increase in week 12 trough FEV1 with GLY+SAL/FP versus PLA+SAL/FP (LSMdiff 101 mL, p<0.001). At 12 weeks, GLY+SAL/FP produced significant improvement in St George's Respiratory Questionnaire total score versus PLA+SAL/FP (LSMdiff -2.154, p=0.02). GLY+SAL/FP demonstrated significant rescue medication reduction versus PLA+SAL/FP (LSMdiff -0.72 puffs/day, p<0.001). Serious adverse events were similar for GLY+SAL/FP, TIO+SAL/FP and PLA+SAL/FP with an incidence of 5.8%, 8.5% and 5.8%, respectively.

Conclusions: GLY+SAL/FP showed comparable improvements in lung function, health status and rescue medication to TIO+SAL/FP. Importantly, addition of GLY to SAL/FP demonstrated significant improvements in lung function, health status and rescue medication compared to SAL/FP.

Trial Registration Number: NCT01513460.

Citing Articles

Outcomes Following Initiation of Triple Therapy with Fluticasone Furoate/Umeclidinium/Vilanterol versus Multiple-Inhaler Triple Therapy Among Medicare Advantage with Part D Beneficiaries and Those Commercially Enrolled for Health Care Insurance in....

Bogart M, Bengtson L, Johnson M, Bunner S, Gronroos N, DiRocco K Int J Chron Obstruct Pulmon Dis. 2024; 19:97-110.

PMID: 38226396 PMC: 10789573. DOI: 10.2147/COPD.S424497.

The Management of Acute Exacerbations in COPD: A Retrospective Observational Study and Clinical Audit.

Boesing M, Ottensarendt N, Luthi-Corridori G, Leuppi J J Clin Med. 2024; 13(1).

PMID: 38202025 PMC: 10779377. DOI: 10.3390/jcm13010019.

Real-World Experience of Treating Chronic Obstructive Pulmonary Disease with Triple Therapy.

Liao K, Wang J, Ho C Int J Chron Obstruct Pulmon Dis. 2023; 18:1057-1066.

PMID: 37309394 PMC: 10257929. DOI: 10.2147/COPD.S404039.

Different inhaled corticosteroid doses in triple therapy for chronic obstructive pulmonary disease: systematic review and Bayesian network meta-analysis.

Lee H, Park H, Jang E, Lee C Sci Rep. 2022; 12(1):15698.

PMID: 36127353 PMC: 9489688. DOI: 10.1038/s41598-022-18353-y.

Efficacy of ICS versus Non-ICS Combination Therapy in COPD: A Meta-Analysis of Randomised Controlled Trials.

Ding Y, Sun L, Wang Y, Zhang J, Chen Y Int J Chron Obstruct Pulmon Dis. 2022; 17:1051-1067.

PMID: 35547781 PMC: 9084385. DOI: 10.2147/COPD.S347588.

References

Dahl R, Chung K, Buhl R, Magnussen H, Nonikov V, Jack D . Efficacy of a new once-daily long-acting inhaled beta2-agonist indacaterol versus twice-daily formoterol in COPD. Thorax. 2010; 65(6):473-9. DOI: 10.1136/thx.2009.125435. View

Chapman K, Beeh K, Beier J, Bateman E, DUrzo A, Nutbrown R . A blinded evaluation of the efficacy and safety of glycopyrronium, a once-daily long-acting muscarinic antagonist, versus tiotropium, in patients with COPD: the GLOW5 study. BMC Pulm Med. 2014; 14:4. PMC: 3907130. DOI: 10.1186/1471-2466-14-4. View

Tashkin D, Celli B, Senn S, Burkhart D, Kesten S, Menjoge S . A 4-year trial of tiotropium in chronic obstructive pulmonary disease. N Engl J Med. 2008; 359(15):1543-54. DOI: 10.1056/NEJMoa0805800. View

Mahler D, Wire P, Horstman D, Chang C, Yates J, Fischer T . Effectiveness of fluticasone propionate and salmeterol combination delivered via the Diskus device in the treatment of chronic obstructive pulmonary disease. Am J Respir Crit Care Med. 2002; 166(8):1084-91. DOI: 10.1164/rccm.2112055. View

Bourbeau J, Sebaldt R, Day A, Bouchard J, Kaplan A, Hernandez P . Practice patterns in the management of chronic obstructive pulmonary disease in primary practice: the CAGE study. Can Respir J. 2008; 15(1):13-9. PMC: 2677850. DOI: 10.1155/2008/173904. View

DUrzo A, Ferguson G, van Noord J, Hirata K, Martin C, Horton R . Efficacy and safety of once-daily NVA237 in patients with moderate-to-severe COPD: the GLOW1 trial. Respir Res. 2011; 12:156. PMC: 3266210. DOI: 10.1186/1465-9921-12-156. View

Calverley P, Anderson J, Celli B, Ferguson G, Jenkins C, Jones P . Salmeterol and fluticasone propionate and survival in chronic obstructive pulmonary disease. N Engl J Med. 2007; 356(8):775-89. DOI: 10.1056/NEJMoa063070. View

Hanania N, Crater G, Morris A, Emmett A, ODell D, Niewoehner D . Benefits of adding fluticasone propionate/salmeterol to tiotropium in moderate to severe COPD. Respir Med. 2011; 106(1):91-101. DOI: 10.1016/j.rmed.2011.09.002. View

Calverley P, Pauwels R, Vestbo J, Jones P, Pride N, Gulsvik A . Combined salmeterol and fluticasone in the treatment of chronic obstructive pulmonary disease: a randomised controlled trial. Lancet. 2003; 361(9356):449-56. DOI: 10.1016/S0140-6736(03)12459-2. View

10.

Magnussen H, Watz H, Kirsten A, Decramer M, Dahl R, Calverley P . Stepwise withdrawal of inhaled corticosteroids in COPD patients receiving dual bronchodilation: WISDOM study design and rationale. Respir Med. 2014; 108(4):593-9. DOI: 10.1016/j.rmed.2014.01.002. View

11.

Welte T, Miravitlles M, Hernandez P, Eriksson G, Peterson S, Polanowski T . Efficacy and tolerability of budesonide/formoterol added to tiotropium in patients with chronic obstructive pulmonary disease. Am J Respir Crit Care Med. 2009; 180(8):741-50. DOI: 10.1164/rccm.200904-0492OC. View

12.

Beeh K, Singh D, Di Scala L, Drollmann A . Once-daily NVA237 improves exercise tolerance from the first dose in patients with COPD: the GLOW3 trial. Int J Chron Obstruct Pulmon Dis. 2012; 7:503-13. PMC: 3430121. DOI: 10.2147/COPD.S32451. View

13.

Rodrigo G, Plaza V, Castro-Rodriguez J . Comparison of three combined pharmacological approaches with tiotropium monotherapy in stable moderate to severe COPD: a systematic review. Pulm Pharmacol Ther. 2011; 25(1):40-7. DOI: 10.1016/j.pupt.2011.10.006. View

14.

Bateman E, Ferguson G, Barnes N, Gallagher N, Green Y, Henley M . Dual bronchodilation with QVA149 versus single bronchodilator therapy: the SHINE study. Eur Respir J. 2013; 42(6):1484-94. PMC: 3844137. DOI: 10.1183/09031936.00200212. View

15.

Karner C, Cates C . Combination inhaled steroid and long-acting beta(2)-agonist in addition to tiotropium versus tiotropium or combination alone for chronic obstructive pulmonary disease. Cochrane Database Syst Rev. 2011; (3):CD008532. PMC: 4170905. DOI: 10.1002/14651858.CD008532.pub2. View

16.

White P, Thornton H, Pinnock H, Georgopoulou S, Booth H . Overtreatment of COPD with inhaled corticosteroids--implications for safety and costs: cross-sectional observational study. PLoS One. 2013; 8(10):e75221. PMC: 3806778. DOI: 10.1371/journal.pone.0075221. View

17.

Aaron S, Vandemheen K, Fergusson D, Maltais F, Bourbeau J, Goldstein R . Tiotropium in combination with placebo, salmeterol, or fluticasone-salmeterol for treatment of chronic obstructive pulmonary disease: a randomized trial. Ann Intern Med. 2007; 146(8):545-55. DOI: 10.7326/0003-4819-146-8-200704170-00152. View

18.

Fang L, Liang X, Zhang J, Liu L, Fu W, Zhao Z . [Combination of inhaled salmeterol/fluticasone and tiotropium in the treatment of chronic obstructive pulmonary disease: a randomised controlled trial]. Zhonghua Jie He He Hu Xi Za Zhi. 2008; 31(11):811-4. View

19.

Wedzicha J, Calverley P, Seemungal T, Hagan G, Ansari Z, Stockley R . The prevention of chronic obstructive pulmonary disease exacerbations by salmeterol/fluticasone propionate or tiotropium bromide. Am J Respir Crit Care Med. 2007; 177(1):19-26. DOI: 10.1164/rccm.200707-973OC. View

20.

Jung K, Park H, Park S, Kim S, Kim Y, Shim J . Comparison of tiotropium plus fluticasone propionate/salmeterol with tiotropium in COPD: a randomized controlled study. Respir Med. 2011; 106(3):382-9. DOI: 10.1016/j.rmed.2011.09.004. View